Chronic inflammation drives pathologies associated with type 2 diabetes (T2D) and breast cancer. Obesity-driven inflammation may explain increased risk and mortality of breast cancer with T2D reported in the epidemiology literature. Therapeutic approaches to target inflammation in both T2D and cancer have so far fallen short of the expected improvements in disease pathogenesis or outcomes. The targeting of epigenetic regulators of cytokine transcription and cytokine signaling offers one promising, untapped approach to treating diseases driven by inflammation. Recent work has deeply implicated the Bromodomain and Extra-Terminal domain (BET) proteins, which are acetylated histone “readers”, in epigenetic regulation of inflammation. This review focuses on inflammation associated with T2D and breast cancer, and the possibility of targeting BET proteins as an approach to regulating inflammation in the clinic. Understanding inflammation in the context of BET protein regulation may provide a basis for designing promising therapeutics for T2D and breast cancer.
|Number of pages||13|
|Journal||Cellular and Molecular Life Sciences|
|State||Published - Aug 4 2016|
Bibliographical noteFunding Information:
This work was supported by Grants from the National Institutes of Health: R56 DK090455 and U01 CA182898 (GVD); R21 DK089270 (BSN); Hematology Training Program T32 HL007501; and Immunology Training Program T32 AI089673.
© 2016, Springer International Publishing.
- Chromatin reader
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Cellular and Molecular Neuroscience
- Cell Biology